Drug Trial Radar · NCT07500298
Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
41
Planned (sponsor's estimate)
Start
May 20, 2026
Primary completion
Dec 27, 2030
Study completion Dec 27, 2032
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sanofi
- First posted
- Mar 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To learn if SAR445877 in combination with FOLFOX6 and bevacizumab can be safely given to patients with advanced MSS CRC.
Conditions
- Phase 1
- SAR445877
- FOlfox6
- Bevacizimab
- First Line Treatment
- Metastatic Colorectal Cancer (CRC)
- Microsatellite Stable
Interventions
SAR445877Drug
Given by IV
FOLFOX6Drug
Given by IV
BevacizumabDrug
Given by IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and adverse events (AEs)Time frame: Through study completion; an average of 1 year.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
MD Anderson Cancer Center
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.